Mucormycosis in trauma patients.
Cutaneous mucormycosis is a rare but often fatal infection in trauma patients. We retrospectively reviewed a 9-year experience with mucormycosis among injured patients. Eleven patients had biopsy- or culture-proven mucormycosis. Nine patients were victims of blunt trauma, two patients had burns measuring greater than 50% TBSA. No patient was at increased risk because of underlying disease or immunosuppression prior to injury. All 11 patients had open wounds on admission. Four patients died of mucormycosis. All nonsurvivors had phycomycotic gangrenous cellulitis of the head, the trunk, or both. In contrast, survivors had involvement of only the extremities. Because of underlying disease, contaminating wounds, antibiotic use, or immunocompromise secondary to shock and sepsis, trauma patients are at risk of developing mucormycosis. To successfully treat mucormycosis, diagnosis must be prompt and accompanied by aggressive debridement and parenteral administration of amphotericin B.
Cocanour
C S
CS
Department of Surgery, University of Texas Medical School Houston.
Miller-Crotchett
P
P
Reed
R L
RL
Johnson
P C
PC
Fischer
R P
RP
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000671:Amputation, Surgical; D003131:Combined Modality Therapy; D003646:Debridement; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000150:complications* / Q000401:mortality / Q000628:therapy; D014946:Wound Infection / Q000382:microbiology*; D014947:Wounds and Injuries / Q000150:complications*
D000666:Amphotericin B